190 related articles for article (PubMed ID: 30340140)
1. Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
Ghosh AK; Jadhav RD; Simpson H; Kovela S; Osswald H; Agniswamy J; Wang YF; Hattori SI; Weber IT; Mitsuya H
Eur J Med Chem; 2018 Dec; 160():171-182. PubMed ID: 30340140
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
[TBL] [Abstract][Full Text] [Related]
3. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
[TBL] [Abstract][Full Text] [Related]
4. Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
Ghosh AK; Parham GL; Martyr CD; Nyalapatla PR; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2013 Sep; 56(17):6792-802. PubMed ID: 23947685
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.
Ghosh AK; Yu X; Osswald HL; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2015 Jul; 58(13):5334-43. PubMed ID: 26107245
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.
Ghosh AK; Williams JN; Ho RY; Simpson HM; Hattori SI; Hayashi H; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 Nov; 61(21):9722-9737. PubMed ID: 30354121
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Qiu X; Zhao GD; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
[TBL] [Abstract][Full Text] [Related]
11. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
[TBL] [Abstract][Full Text] [Related]
13. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Takayama J; Baldridge A; Leshchenko-Yashchuk S; Miller HB; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
Org Biomol Chem; 2008 Oct; 6(20):3703-13. PubMed ID: 18843400
[TBL] [Abstract][Full Text] [Related]
14. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
[TBL] [Abstract][Full Text] [Related]
15. Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
Ghosh AK; Williams JN; Kovela S; Takayama J; Simpson HM; Walters DE; Hattori SI; Aoki M; Mitsuya H
Bioorg Med Chem Lett; 2019 Sep; 29(18):2565-2570. PubMed ID: 31416666
[TBL] [Abstract][Full Text] [Related]
16. Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
Ghosh AK; Chapsal BD; Parham GL; Steffey M; Agniswamy J; Wang YF; Amano M; Weber IT; Mitsuya H
J Med Chem; 2011 Aug; 54(16):5890-901. PubMed ID: 21800876
[TBL] [Abstract][Full Text] [Related]
17. Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.
Ghosh AK; Brindisi M; Nyalapatla PR; Takayama J; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem; 2017 Oct; 25(19):5114-5127. PubMed ID: 28434781
[TBL] [Abstract][Full Text] [Related]
18. Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.
Ghosh AK; Mishevich JL; Kovela S; Shaktah R; Ghosh AK; Johnson M; Wang YF; Wong-Sam A; Agniswamy J; Amano M; Takamatsu Y; Hattori SI; Weber IT; Mitsuya H
Eur J Med Chem; 2023 Jul; 255():115385. PubMed ID: 37150084
[TBL] [Abstract][Full Text] [Related]
19. Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.
Ghosh AK; Osswald HL; Glauninger K; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
J Med Chem; 2016 Jul; 59(14):6826-37. PubMed ID: 27389367
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
Ghosh AK; Chapsal BD; Baldridge A; Steffey MP; Walters DE; Koh Y; Amano M; Mitsuya H
J Med Chem; 2011 Jan; 54(2):622-34. PubMed ID: 21194227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
